Afatinib Dimaleate
GILOTRIF®

About GILOTRIF®
-
Marketed by Boehringer Ingelheim Pharmaceuticals, Inc
-
Orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family
-
First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations
Review and approval status
July 12, 2013
First U.S. approval
September 25, 2013
First E.U. approval
Constraint date forecast:
- 2026: Patent expiry: United States
- 2026: SPC expiry: European Union
- 2026: Patent expiry: Japan
API availability


*Source: Cortellis Generics Intelligence